A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.52 USD -1.95% Market Closed
Market Cap: 321m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Net Margin
Aquestive Therapeutics Inc

-59.8%
Current
-87%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-59.8%
=
Net Income
-35.2m
/
Revenue
58.9m

Net Margin Across Competitors

Country US
Market Cap 320.9m USD
Net Margin
-60%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Aquestive Therapeutics Inc
Glance View

Market Cap
320.9m USD
Industry
Pharmaceuticals

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

AQST Intrinsic Value
2.06 USD
Overvaluation 42%
Intrinsic Value
Price
A

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-59.8%
=
Net Income
-35.2m
/
Revenue
58.9m
What is the Net Margin of Aquestive Therapeutics Inc?

Based on Aquestive Therapeutics Inc's most recent financial statements, the company has Net Margin of -59.8%.